Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, CellSource Co's Enterprise Value is 円1,570 Mil.
CellSource Co's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 was 円196 Mil. Therefore, CellSource Co's EV-to-EBIT ratio for today is 8.00.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, CellSource Co's Enterprise Value is 円1,570 Mil.
CellSource Co's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 was 円384 Mil. Therefore, CellSource Co's EV-to-EBITDA ratio for today is 4.09.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, CellSource Co's Enterprise Value is 円1,570 Mil.
CellSource Co's Revenue for the trailing twelve months (TTM) ended in Apr. 2026 was 円3,667 Mil. Therefore, CellSource Co's EV-to-Revenue ratio for today is 0.43.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, CellSource Co's Enterprise Value is 円1,570 Mil.
CellSource Co's Free Cash Flow for the trailing twelve months (TTM) ended in Apr. 2026 was 円322 Mil. Therefore, CellSource Co's EV-to-FCF ratio for today is 4.88.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
CellSource Co (TSE:4880) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
CellSource Co's current Enterprise Value is 円1,570 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. CellSource Co's EBIT for the trailing twelve months (TTM) ended in Apr. 2026 was 円196 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
CellSource Co's current Enterprise Value is 円1,570 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. CellSource Co's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 was 円384 Mil.
CellSource Co's current Enterprise Value is 円1,570 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. CellSource Co's Revenue for the trailing twelve months (TTM) ended in Apr. 2026 was 円3,667 Mil.
CellSource Co's current Enterprise Value is 円1,570 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. CellSource Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Apr. 2026 was 円446 Mil.
CellSource Co's current Enterprise Value is 円1,570 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. CellSource Co's Free Cash Flow for the trailing twelve months (TTM) ended in Apr. 2026 was 円322 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellSource Co Enterprise Value Related Terms
CellSource Co Enterprise Value Historical Data
* Premium members only.
The historical data trend for CellSource Co's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4880 vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, CellSource Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSource Co Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSource Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where CellSource Co's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
CellSource Co's Enterprise Value for the fiscal year that ended in Oct. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellSource Co (TSE:4880) has a Enterprise Value of 円1,570 Mil as of Jul. 09, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on CellSource Co and its competitors.
Is CellSource Co's Enterprise Value too high?
CellSource Co's current Enterprise Value is 円1,570 Mil. Overall, CellSource Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's Enterprise Value compare to VRTX and REGN?
CellSource Co's Enterprise Value of 円1,570 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on CellSource Co and its competitors. CellSource Co's current Enterprise Value is 円1,570 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円781.48, compared to a current price of 円319.00 — trading 59.2% below its estimated fair value. The current Enterprise Value is 円1,570 Mil. CellSource Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current Enterprise Value is 円1,570 Mil as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSource Co (TSE:4880) Overvalued in 2026?
Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued.
The current stock price of 円319.00 is trading 59.2% below its estimated GF Value™ of 円781.48.
GuruFocus considers CellSource Co to be Significantly Undervalued.
Key valuation signals for TSE:4880:
Enterprise Value: 円1,570 Mil
GF Value™: 円781.48 vs. price of 円319.00 (59.2% below fair value)
No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
69GF Score
Get the complete analysis for TSE:4880
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4880 has been successfully added to your 
